Condition: Solid Tumors · Sponsor: Incyte Corporation
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| Investigative Site US058 | Birmingham, Alabama, United States | Not Yet Recruiting |
| Investigative Site US016 | Anchorage, Alaska, United States | Recruiting |
| Investigative Site US026 | Chandler, Arizona, United States | Not Yet Recruiting |
| Investigative Site US045 | Tucson, Arizona, United States | Not Yet Recruiting |
| Investigative Site US051 | Duarte, California, United States | Not Yet Recruiting |
| Investigative Site US048 | Fountain Valley, California, United States | Not Yet Recruiting |
| Investigative Site US049 | Irvine, California, United States | Not Yet Recruiting |
| Investigative Site US054 | La Jolla, California, United States | Not Yet Recruiting |
| Investigative Site US027 | Los Angeles, California, United States | Recruiting |
| Investigative Site US036 | Los Angeles, California, United States | Recruiting |
| Investigative Site US034 | San Francisco, California, United States | Not Yet Recruiting |
| Investigative Site US001 | Santa Monica, California, United States | Not Yet Recruiting |
+ 203 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07522073